New Hampton, New York. January 3, 2018. Balchem Corporation (NASDAQ: BCPC), the global leader in choline and precision release nutrient technologies, recently engaged the Sedona group to supplement the ruminant sales team. This group will support the current sales force and focus on educating dairy producers, veterinarians and nutritionists on the benefits of feeding ReaShure® Precision Release Choline to transition dairy cows.
New research recently published by the University of Florida demonstrates how cows fed ReaShure during the transition period had higher peaks and produced an additional 4.6 pounds of milk per day during the 40-week trial period. ReaShure helped launch the cow’s lactation during the critical transition, allowing cows to accelerate quickly to reach the highest possible peak and then follow a sustained glide path through the remainder of the lactation. If we extrapolate the research results over a 305-day lactation, the outcome is an additional 1,403 lbs. of milk per cow per year.
The new team will cover New York, Pennsylvania, Iowa, North Dakota, South Dakota, Nebraska, Minnesota, Wisconsin and Michigan, working closely with nutritionists, veterinarians and dairy producers.
Segment Information Balchem Corporation reports four business segments: Human Nutrition & Health; Animal Nutrition & Health; Specialty Products; and Industrial Products. The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. The Industrial Products segment manufactures and supplies certain derivative products into industrial applications.
Forward-Looking Statements This release contains forward-looking statements, which reflect Balchem’s expectation or belief concerning future events that involve risks and uncertainties. Balchem can give no assurance that the expectations reflected in forward-looking statements will prove correct and various factors could cause results to differ materially from Balchem’s expectations, including risks and factors identified in Balchem’s annual report on Form 10-K for the year ended December 31, 2016. Forward-looking statements are qualified in their entirety by the above cautionary statement. Balchem assumes no duty to update its outlook or other forward-looking statements as of any future date.
Contact: Mary Ann Brush, Balchem Corporation Telephone: 845-326-5600
Ted Harris, Chairman, President and CEO said, "We delivered solid second quarter financials with record earnings from operations and adjusted EBITDA. I am particularly pleased with the excellent performance in our Human Nutrition and Health and Specialty Products segments, both delivering strong sales and earnings growth."
Join Ted Harris, Chairman of the Board, President, and CEO and Martin Bengtsson, CFO on Friday, October 25, 2024, at 11:00 AM Eastern Time (ET) to review 3rd Quarter 2024 financial results.
×
You are leaving the Balchem Corporation website and linking to a non-affiliated third-party site.
